# NM_004327.4(BCR):c.3021G>A (p.Pro1007=)

https://sugi.bio/variant/bcr-p-pro1007

## Summary

**BCR p.Pro1007= (c.3021G>A)** is classified **Benign/Likely benign** in BCR (ClinVar, Multiple submitters, 3 submitters; last evaluated 2024-11-26). Rare (popmax 0.43%, nfe).

**At a glance:** Benign/Likely benign · review: Multiple submitters · rsID rs11558694 · 3 submitters · rare (popmax 0.43%, nfe)

## For patients & families {#patients}

This is a change in the BCR gene that is classified as benign/likely benign — not considered disease-causing, submitted by 3 submitters.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [BCR](https://sugi.bio/atlas/gene/BCR/) |
| Protein change (HGVS p.) | p.Pro1007= |
| Coding change (HGVS c.) | c.3021G>A |
| MANE Select transcript | [NM_004327](https://www.ncbi.nlm.nih.gov/nuccore/NM_004327) |
| dbSNP | [rs11558694](https://www.ncbi.nlm.nih.gov/snp/rs11558694/) |
| Variant type | single nucleotide variant |
| Location | chr22:23309432-23309432 (GRCh38) |
| ClinVar | [VCV710829](https://www.ncbi.nlm.nih.gov/clinvar/variation/710829/) |

**All HGVS expressions:** `LRG_1112:g.134068G>A`, `LRG_1112t1:c.3021G>A`, `NC_000022.10:g.23651619G>A`, `NC_000022.11:g.23309432G>A`, `NG_009244.2:g.134068G>A`, `NM_004327.4:c.3021G>A`, `NM_021574.3:c.2889G>A`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP -2.389, GERP -3.35 — fast-evolving / accelerated position
- CADD: **PHRED 10.45**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **0.43%** (nfe) · FAF95 0.42% · FAF99 0.416% · 5,009/1,164,512 in the highest group · 5,831/1,588,124 alleles overall — rare (popmax 0.43%, nfe).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Amish (not grpmax-eligible) | 6.56% | 15 |
| Remaining individuals (not grpmax-eligible) | 0.437% | 229 |
| European (non-Finnish) (grpmax) | 0.43% | 232 |
| Finnish (not grpmax-eligible) | 0.258% | 387 |
| South Asian | 0.164% | 610 |
| Admixed American | 0.15% | 668 |
| Middle Eastern | 0.126% | 794 |
| African / African-American | 0.114% | 873 |
| East Asian | 0.0184% | 5,446 |
| Ashkenazi Jewish (not grpmax-eligible) | 0.00686% | 14,576 |

Amish shows a higher raw frequency than the grpmax group. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and "Remaining individuals" — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**BCR** population constraint: LOEUF 0.608, pLI 6.2898e-06, missense-Z -0.17793; ClinGen dosage — haploinsufficiency 0, triplosensitivity 0 (0–3 scale). *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

## Protein context {#protein}

Residue **1007** lies in the c2 domain.

AlphaFold model confidence (whole protein): pLDDT 65.61, 23% of residues very-high.

**5 experimental structure(s)** (PDB): [1K1F](https://www.rcsb.org/structure/1K1F), [2AIN](https://www.rcsb.org/structure/2AIN), [5N6R](https://www.rcsb.org/structure/5N6R), [5N7E](https://www.rcsb.org/structure/5N7E), [5OC7](https://www.rcsb.org/structure/5OC7).

## What this gene does {#gene-function}

*Describes the biological roles of BCR (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** BCR's established molecular role includes guanyl-nucleotide exchange factor activity. p.Pro1007= falls in the c2 domain. In Reactome, BCR is annotated in disease pathway(s) including **Signaling by FGFR1 in disease**, **Signaling by cytosolic FGFR1 fusion mutants**.

**Disease mechanism (Reactome):** BCR loss or alteration is curated in [Signaling by FGFR1 in disease](https://reactome.org/content/detail/R-HSA-5655302), [Signaling by cytosolic FGFR1 fusion mutants](https://reactome.org/content/detail/R-HSA-1839117).

### Pathways affected {#pathways}

BCR participates in **9 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| ⚕ [Signaling by FGFR1 in disease](https://reactome.org/content/detail/R-HSA-5655302) | curated |
| ⚕ [Signaling by cytosolic FGFR1 fusion mutants](https://reactome.org/content/detail/R-HSA-1839117) | curated |
| [CDC42 GTPase cycle](https://reactome.org/content/detail/R-HSA-9013148) | curated |
| [RAC1 GTPase cycle](https://reactome.org/content/detail/R-HSA-9013149) | curated |
| [RAC2 GTPase cycle](https://reactome.org/content/detail/R-HSA-9013404) | curated |
| [RAC3 GTPase cycle](https://reactome.org/content/detail/R-HSA-9013423) | curated |
| [RHOA GTPase cycle](https://reactome.org/content/detail/R-HSA-8980692) | curated |
| [RHOB GTPase cycle](https://reactome.org/content/detail/R-HSA-9013026) | curated |
| [RHOC GTPase cycle](https://reactome.org/content/detail/R-HSA-9013106) | curated |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** guanyl-nucleotide exchange factor activity, GTPase activator activity.

**Biological process:** small GTPase-mediated signal transduction, keratinocyte differentiation, regulation of Rho protein signal transduction, focal adhesion assembly, activation of GTPase activity.

## Clinical significance {#significance}

**Benign/Likely benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2024-11-26.

**Submitter consensus:** conflicting (2 Benign, 1 Likely benign).

**Submission history:** 3 submissions (2018–2024); classifications have differed over time.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Labcorp Genetics (formerly Invitae), Labcorp | Benign | criteria provided, single submitter | clinical testing | 2018-07-23 |
| Breakthrough Genomics, Breakthrough Genomics | Benign | criteria provided, single submitter | not provided |  |
| Blueprint Genetics | Likely benign | criteria provided, single submitter | clinical testing | 2024-11-26 |

**Reported phenotype names (ClinVar):** not provided, not specified, AllHighlyPenetrant, none provided.

## Similar variants {#similar}

Related BCR variant pages (same residue, condition, or type): [BCR p.Pro1007Leu](/variant/bcr-p-pro1007leu), [BCR p.Ser356Arg](/variant/bcr-p-ser356arg), [BCR c.2116-6C>G](/variant/bcr-c-2116-minus-6c-g), [BCR c.2116-7C>A](/variant/bcr-c-2116-minus-7c-a), [BCR c.2526+7G>T](/variant/bcr-c-2526-plus-7g-t), [BCR c.3073-8T>C](/variant/bcr-c-3073-minus-8t-c), [BCR c.3183-4G>A](/variant/bcr-c-3183-minus-4g-a), [BCR p.Ala1257=](/variant/bcr-p-ala1257).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-11); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-07-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 710829). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*